骨髓瘤分期和风险预测的过去、现在和未来。

IF 4.2 2区医学 Q1 ONCOLOGY

Oncologist Pub Date : 2025-09-19 DOI:10.1093/oncolo/oyaf299

Mehmet Baysal, Kelley Julian, Douglas Sborov, Amandeep Godara, Brian McClune, Jens G Lohr, Gliceida Galarza Fortuna, Ghulam Rehman Mohyuddin

{"title":"骨髓瘤分期和风险预测的过去、现在和未来。","authors":"Mehmet Baysal, Kelley Julian, Douglas Sborov, Amandeep Godara, Brian McClune, Jens G Lohr, Gliceida Galarza Fortuna, Ghulam Rehman Mohyuddin","doi":"10.1093/oncolo/oyaf299","DOIUrl":null,"url":null,"abstract":"With the emergence of several new staging and risk stratification systems in myeloma, we have explored the evolution of these frameworks-past, present, and future. We examine how staging systems have evolved over time, the strengths of current models, and the limitations that future research can address to further improve prognostication.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Past, Present and Future of Myeloma Staging and Risk Prognostication.\",\"authors\":\"Mehmet Baysal, Kelley Julian, Douglas Sborov, Amandeep Godara, Brian McClune, Jens G Lohr, Gliceida Galarza Fortuna, Ghulam Rehman Mohyuddin\",\"doi\":\"10.1093/oncolo/oyaf299\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"With the emergence of several new staging and risk stratification systems in myeloma, we have explored the evolution of these frameworks-past, present, and future. We examine how staging systems have evolved over time, the strengths of current models, and the limitations that future research can address to further improve prognostication.\",\"PeriodicalId\":54686,\"journal\":{\"name\":\"Oncologist\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncologist\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/oncolo/oyaf299\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf299","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

随着几个新的骨髓瘤分期和风险分层系统的出现，我们已经探索了这些框架的演变-过去，现在和未来。我们研究了分期系统是如何随着时间的推移而演变的，当前模型的优势，以及未来研究可以解决的局限性，以进一步改善预测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Past, Present and Future of Myeloma Staging and Risk Prognostication.

With the emergence of several new staging and risk stratification systems in myeloma, we have explored the evolution of these frameworks-past, present, and future. We examine how staging systems have evolved over time, the strengths of current models, and the limitations that future research can address to further improve prognostication.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncologist 医学-肿瘤学

CiteScore

10.40

自引率

3.40%

发文量

309

审稿时长

3-8 weeks

期刊介绍： The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.